- Home
- COEP vs CRIS Comparison
COEP vs CRIS Comparison
Compare COEP & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- CRIS
- Stock Information
- Founded
- COEP 2017
- CRIS 2000
- Country
- COEP United States
- CRIS United States
- Employees
- COEP N/A
- CRIS N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COEP Health Care
- CRIS Health Care
- Exchange
- COEP Nasdaq
- CRIS Nasdaq
- Market Cap
- COEP 32.0M
- CRIS 21.3M
- IPO Year
- COEP N/A
- CRIS 2000
- Fundamental
- Price
- COEP $7.83
- CRIS $2.32
- Analyst Decision
- COEP
- CRIS Strong Buy
- Analyst Count
- COEP 0
- CRIS 2
- Target Price
- COEP N/A
- CRIS $16.50
- AVG Volume (30 Days)
- COEP 29.1K
- CRIS 71.8K
- Earning Date
- COEP 08-15-2025
- CRIS 07-31-2025
- Dividend Yield
- COEP N/A
- CRIS N/A
- EPS Growth
- COEP N/A
- CRIS N/A
- EPS
- COEP N/A
- CRIS N/A
- Revenue
- COEP $62,874.00
- CRIS $11,202,000.00
- Revenue This Year
- COEP N/A
- CRIS N/A
- Revenue Next Year
- COEP N/A
- CRIS $10.67
- P/E Ratio
- COEP N/A
- CRIS N/A
- Revenue Growth
- COEP N/A
- CRIS 14.17
- 52 Week Low
- COEP $2.31
- CRIS $1.02
- 52 Week High
- COEP $13.70
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- COEP 43.91
- CRIS 52.52
- Support Level
- COEP $6.80
- CRIS $2.11
- Resistance Level
- COEP $8.86
- CRIS $2.26
- Average True Range (ATR)
- COEP 0.62
- CRIS 0.21
- MACD
- COEP -0.05
- CRIS -0.04
- Stochastic Oscillator
- COEP 45.88
- CRIS 21.36
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.